MAGiC Ablation Catheter
Stereotaxis, Inc. · Decision date Jan 5, 2026
What did the FDA approve?
FDA records P240014 as an original PMA application. The recorded decision is approval, dated Jan 5, 2026.
FDA approval order statement
approval for the MAGiC Ablation Catheter. This device is indicated for: The MAGiC Magnetic Interventional Ablation Catheter is indicated for cardiac electrophysiological mapping, delivering diagnostic pacing stimuli, and for the creation of endocardial lesions to treat supraventricular tachycardia (e.g., macroreentrant atrial tachycardia, focal atrial tachycardia, atrioventricular nodal reentrant tachycardia, and atrioventricular reentrant tachycardia) in patients with congenital heart disease in whom vascular or target chamber access by conventional manual catheter navigation is limited due to underlying anatomic abnormalities and/or previous surgical interventions.
- Regulatory pathway
- Original PMA
- Clinical specialty
- Cardiovascular
- Decision date
- Jan 5, 2026
Regulatory record facts
- Identifier
- P240014
- Regulatory pathway
- Premarket approval application
- Applicant
- Stereotaxis, Inc.
- Product code
- LPB
- Decision code
- APPR
- Decision date
- Jan 5, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Cardiac ablation percutaneous catheter.
- Applicant
- Stereotaxis, Inc.
- Product code
- LPB
- FDA device class
- 3
The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.
FDA decision timeline
P240014 received
Application receipt date recorded by FDA.
P240014 · FDA decision
APPR
P240014/S001 · Related supplement
MAGiC Ablation Catheter
Timeline entries are records held by MedtechLedger for P240014. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P240014
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
MAGiC Ablation CatheterP240014/S001 | Stereotaxis, Inc. | PMA supplement | Jul 31, 2026 | FDA |
Explore the linked device profile
Other records with product code LPB
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Biosense Webster, Inc. | PMA supplement | Sep 15, 2026 | FDA | |
| Irvine Biomedical, Inc. | PMA supplement | Sep 3, 2026 | FDA | |
Ampere GeneratorP040014/S051 | Irvine Biomedical, Inc. | PMA supplement | Aug 7, 2026 | FDA |
Ampere GeneratorP960016/S094 | St Jude Medical | PMA supplement | Aug 7, 2026 | FDA |
| Medtronic Cryocath, LP | PMA supplement | Apr 23, 2026 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Stereotaxis, Inc.
- Headquarters
- Not reported
- Brand website
- Not reported
- FDA applicant address
- 710 Tucker Blvd., Suite 110, Saint Louis, MO, 63101
Sources and methodology
- Original FDA record: P240014
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 20, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records


